Toxoplasmosis, caused by Toxoplasma gondii (T. gondii), remains a significant public health problem. Recently, it has been shown that the antigens targeting the dendritic cells (DCs) is a promising way to enhance the immune responses against pathogens and tumors. In this study, we constructed and evaluated a new DNA vaccine of T. gondii, based on the major surface antigen SAG1 of T. gondii and an antibody single-chain fragment variable (scFv) directed against the mouse DEC 205, an endocytic receptor expressed on the surface of DCs and other cells. The constructs were tested in vitro to express the encoded proteins, then the cellular and humoral immune responses were analyzed, and the protective efficacy of the vaccine was evaluated. Our results showed that the plasmid encoding the fusion of DEC-205 scFv with SAG1 significantly enhanced the SAG1-specific immune response and DC targeting could elicit the Th1 type immune response, evidenced by the high level of IFN-γ, IL-2 and IgG2a. Therefore, we showed evidence in this research that DEC-205 can be exploited in developing an effective T. gondii vaccine.